

Supplementary Material.

1. Derivation of relative risk values.

Relative risk values are for target lesion revascularization (TLR), and are all relative to percutaneous transluminal angioplasty (PTA) with bail-out bare metal stents. All tables are from: 'Appendix A. Supplementary material; Full outcomes' of Jens *et al*¹

Bare metal stents:

Data are taken from Table '1.4 BARE STENT versus PTA'. Data are taken from two studies^{2;3}. The pooled 12-month TLR rates are 14.0% (26/186) for bare metal stents and 19.3% (36/187) for PTA, providing a relative risk of 0.7261.

Drug eluting balloons:

Data are from Table '3.4 DEB versus PTA'. Data are taken from two studies^{4;5}. The pooled 18 to 24 month TLR rates are 14.0% (13/93) for bare metal stents and 51.0% (49/96) for PTA, providing a relative risk of 0.2739.

Reference List

- (1) Jens S, Conijn AP, Koelemay MJW, Bipat S, Reekers JA. Randomized trials for endovascular treatment of infrainguinal arterial disease: systematic review and meta-analysis (part 1: above the knee). *European Journal of Vascular and Endovascular Surgery* 2014; **47**(5):524-535.
- (2) Zdanowski Z, Albrechtsson U, Lundin A, Jonung T. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions?: A randomized controlled study. *International angiology* 1999; **18**(4):251.
- (3) Krankenberg H, Schlater M, Steinkamp HJ, Bargelin K, Scheinert D, Schulte KL et al. Nitinol Stent Implantation Versus Percutaneous Transluminal Angioplasty in Superficial Femoral Artery Lesions up to 10 cm in Length The Femoral Artery Stenting Trial (FAST). *Circulation* 2007; **116**(3):285-292.
- (4) Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwald U, Beregi JP et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. *New England Journal of Medicine* 2008; **358**(7):689-699.
- (5) Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U et al. Inhibition of restenosis in femoropopliteal arteries paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. *Circulation* 2008; **118**(13):1358-1365.